An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

Prenatal gene therapy via mRNA LNPs fixes faulty genes in fetal brain cells in animal model of neurodevelopmental syndrome.

New research underscores the role of the immune system in depression, linking inflammation to poor response to standard ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Shares of Moderna Inc. MRNA inched 0.55% higher to $53.09 Friday, on what proved to be an all-around mixed trading session ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $52.8 which represents a decrease of $-0.59 or -1.11% from the prior close of $53.39. The stock opened at $53.39 and touched a ...

Researchers are exploring a new mRNA delivery technique to treat genetic conditions in the fetal brain, potentially ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.